Shows
Between the Biotech WavesS2 E7: A Between the Biotech Waves Conversation with Bobby GasparToday’s episode features a remarkable leader in the field of gene therapy, Dr. Bobby Gaspar. With over 25 years of experience as a physician and scientist, Bobby has played a pivotal role in redefining treatment options for severe genetic disorders.As the co-founder and current CEO of Orchard Therapeutics, recently acquired by Kyowa Kirin, Bobby has been at the forefront of advancing gene therapy, particularly in hematopoietic stem cell gene therapy. His groundbreaking work includes some of the earliest studies in patients suffering from severe primary immune deficiencies, propelling these therapies into late-stage clinical trials and bringing hope to...2025-05-0258 minBetween the Biotech WavesS2 E6: A Between the Biotech Waves Conversation with Steve PaulI am thrilled to welcome Steve Paul to Between the Biotech Waves.With nearly 50 years of experience as a physician-scientist, Steve has made significant contributions to the fields of neuroscience, molecular neuropharmacology, and CNS drug discovery and development. He is the scientific co-founder of Sage Therapeutics, where he played a key role as the interim head of Research and Development during its formative stages which ultimately led to the approval of the first drug for postpartum depression. Additionally, he co-founded Voyager Therapeutics, a pioneering company in CNS gene therapy, and served as its president and CEO.Steve’s...2025-04-2556 minBetween the Biotech WavesS2 E5: A Between the Biotech Waves Conversation with Kent RogersToday, I are excited to welcome Kent Rogers, the Chief Executive Officer of EveryONE Medicines. Kent brings a wealth of experience to his new role, having held executive leadership positions at renowned pharmaceutical companies as well as emerging biotech firms. With over 30 years of expertise in brand and generic pharmaceuticals, specialty pharmacy, and healthcare supply chain management, Kent has been at the forefront of developing disruptive solutions that enhance access to new medicines targeting critical disease states.His leadership at EveryONE Medicines focuses on the research, development, and commercialization of individualized precision therapeutics, particularly for children facing rare...2025-04-171h 01Between the Biotech WavesBetween the Biotech Waves - Sound Bite - Bill Hicks Co-Chair Life Sciences Practice MintzSound Bite with Bill Hicks looking at the market and financing in real time.2025-04-1722 minBetween the Biotech WavesBetween the Biotech Waves - Sound Bite - Paul Matteis Equity Analyst StifelWelcome to a Between the Biotech Waves sound bite, a short podcast to provide insight into the rapidly changing biotech environment - I am pleased to welcome Paul Matteis Managing Director, Head of Therapeutics Equity Research in Biotech at Stifel to discuss the current market dynamics affecting our biotech industry. RECORDED April 7th 20252025-04-0826 minBetween the Biotech WavesS2 E4: A Between the Biotech Waves Conversation with Dan LynchIn this episode, I am thrilled to welcome Dan Lynch, an Executive Venture Partner at Google Ventures and a seasoned leader in the biotechnology sector.Since joining GV in 2021, Dan has partnered with life sciences CEOs and executives, providing invaluable guidance as a trusted advisor and coach. His commitment to fostering long-term relationships underscores his belief that collaboration is essential in an industry filled with talented people.Dan brings a wealth of experience, having worked with numerous biopharmaceutical companies, including notable names like ImClone, where he served as CEO and CFO. Under his leadership, ImClone achieved a...2025-02-271h 01Between the Biotech WavesS2 E3: A Between The Biotech Waves Conversation with Stan Crooke, Ionis & N-Lorem FounderIn today's episode, I am honored to welcome Stanley Crooke, the founder and CEO of Ionis Pharmaceuticals the first and leading antisense oligonucleotide biotech and founder, CEO and Chair of N-Lorem, a not for profit entity developing ASOs for ultra rare diseases. Stan is THE pioneer in the field of antisense oligonucleotide based RNA-targeted therapies. With a deep passion for science and innovation, Stan has dedicated his career to transforming the landscape of drug discovery and development, resulting in groundbreaking therapies that address some of the most challenging diseases.Stan's journey in biotechnology is truly inspiring, he comes...2025-02-201h 04Between the Biotech WavesS2 E2: A Between the Biotech Waves Conversation with Peter BarrettWelcome to ‘Between the Biotech Waves,’ the podcast where we navigate the dynamic world of biotechnology and explore the minds driving its innovation. I’m your host, Nessan Bermingham, and today, we have a true visionary in the field, Peter Barrett.Peter is a partner at Atlas Venture, where he has been a key player in the creation of numerous novel therapeutic and drug discovery platform companies. With an unyielding passion for advancing healthcare, Peter has been directly involved in co-founding, building, investing and supporting numerous companies including Celera Genomics, Alynlam Therapeutics and Momenta, to name just a few.2025-01-3153 minBetween the Biotech WavesS2 Episode 1: A conversation with Matt PorteusNow that JPM '25 is behind us, where the weather was great but the mood was somber, back to podcasting!Welcome back to 'Between the Biotech Waves,' the podcast where we explore the frontiers of biotechnology and the remarkable individuals driving innovation. I’m your host, Nessan Bermingham, and today, we are honored to have Dr. Matt Porteus with us, a true pioneer in the field of genome editing.Dr. Porteus is making headlines for his role in the development of Lyfgenia, the groundbreaking CRISPR-Cas9 gene editing drug from Vertex Pharmaceuticals and CRISPR Therapeutics, designed to tr...2025-01-2454 minBetween the Biotech WavesEpisode 35: A Between the Biotech Waves Conversation with Mike Curtis, President & CEO of eGenesisWelcome back to Between the Biotech Waves. I am sorry for the lack of episodes over the past few months, unfortunately life threw me a curve ball that I have been taking care of but now back and ready to go!Today it gives me great pleasure to introduce Mike Curtis, President and CEO of eGenesis. You may recall seeing eGenesis on the front cover of the New York Times recently following the first successful xenotransplantation of a genetically modified porcine kidney. This followed years of work within eGenesis to develop porcine donors for human tissue transplant.2024-07-021h 05Between the Biotech WavesEpisode 33: A Between the Biotech Waves conversation with Eliot Forster, xCEO of F-star TherapeuticsToday I am talking to Eliot Forster xCEO of F-star Therapeutics.Eliot was at helm of the company as they reversed merged into Springbank Pharmaceuticals & through the recently announced acquisition by Sino Biopharma, a transaction that generated a lot of interest given the very public interactions with CFIUS.Prior to F-star, Eliot was CEO of Immunocore, Creabilis and Solace Pharmaceuticals following his multiple roles at Pfizer which included head of development and operations, European Union. He was the founding chair of Medcity and is an honorary visiting professor of molecular and clinical cancer medicine at the University...2023-07-191h 04Between the Biotech WavesEpisode 32: The Triplet Therapeutics story, from concept to birth, life & death.Today we have an unusual (& long) podcast where we talk to key members of the Triplet Therapeutics management team. Triplet was founded to develop antisense oligonucleotides targeting the DNA damage response pathway that has been implicated in driving repeat disorders including Huntington's disease - the lead indication for Triplet. The team discusses the challenges in building the company and what ultimately led to it's demise. 2023-07-191h 45Between the Biotech WavesEpisode 31: A Between the Biotech Waves Conversation with Tim Yu Today we are talking to Tim Yu. Tim is attending physician at the division of genetics and genomics at Boston Children’s Hospital and assoc prof of Pediatrics at Harvard Medical School. The scope of work that Tim does is well beyond what can be covered in this intro however I have gotten to know Tim through his leading the emerging filed of N of 1 plus drugs. Tim worked with Julia Vitarello to develop Milasen leading the way in truly personalized therapeutics. Please join me in welcoming Tim to the podcast. 2023-07-0255 minBetween the Biotech WavesEpisode 30: A Between the Biotech Waves conversation with Barry Greene, CEO of Sage TherapeuticsToday we are talking to Barry Greene, CEO of Sage Therapeutics. Barry has had an amazing career spanning over 30 years in the biotech industry. Prior to Sage Barry was President of Alnylam shepherding it with John through its evolution from basic science through commercial product launch. Prior to ALNY Barry was general manager of Oncology at Millennium where he was directly involved in the approval and launch of Velcade. He is currently a member of the board of the Pharmaceutical Research and Manufacturers of America. 2023-07-0245 minBetween the Biotech WavesEpisode 29: A Between the Biotech Waves conversation with Joel Marcus, Founder & Exec Chair of Alexandria Real EstateToday we are talking to Joel Marcus. He has shaped the life sciences industry through ARE from the buildings we use to venture and fund investing. His impact can be directly seen in major cities across the US from Boston to NY to San Francisco with over 22million sq ft of space. Beyond Alexandria he is a philanthropist who supports veterans and their families, and through his initiatives people suffering from the opioid crisis, homelessness and mental illness. Please join me in welcoming Joel.2023-06-1653 minBetween the Biotech WavesEpisode 28 A Between the Biotech Waves Conversation with Rachel MeyersToday we are talking to Rachel Meyers. Rachel was most recently the CSO of Faze Medicines a company she launched with TRV to focus on the regulation of biomolecular condensates to treat disease. Prior to Faze she was an EIR at TRV prior to which she spent nearly 2 decades at Alnylam. I have had the pleasure of working with Rachel getting an appreciation not only of her as a scientist, entrepreneur and operator but also her pure love of science, focus on company culture and her passion for diversity, equity and inclusion. 2023-06-1657 minBetween the Biotech WavesEpisode 27 A Between the Biotech Waves Conversation with Aoife Brennan, CEO of SynlogicToday we are talking to Aofie Brennan, president and CEO of Synlogic. Aoife was trained as a doctor at Trinity College Dublin following which she moved to the US. After completing her postdoctoral research at Beth Israel Aofie joined TolerX focused on developing autoimmune therapies for type I diabetes. Following which Aoife spent 6 years at Biogen ultimately becoming head of Rare Disease Innovation, she was involved in the development of Spinraza, Alprolix and Eloctate. Aoife moved from Biogen to Synlogic where she initially took the CMO role ultimately being elected as CEO and President of the company. She has...2023-04-261h 06Between the Biotech WavesEpisode 26: A Between the Biotech Waves conversation with Drew WeissmanToday we are talking to Drew Weissman. Drew is the Roberts Family Professor in Vaccine Research at Perelman School of Medicine and Director of the Penn Institute for RNA Innovation at the University of Pennsylvania. Drew has spent his career working on RNA biology and vaccine development. He, along with his colleague Katalin Kariko, have been pivotal in the development of mRNA vaccines most notably the COVID-19 vaccines developed by BioNTech/Pfizer and Moderna. Drew received his MD/PhD from Boston University in 1987, following which he did a residency at Beth Israel and followship at the NIH u...2023-02-0557 minBetween the Biotech WavesEpisode 25: A Between the Biotech Waves conversation with Rodolphe Barrangou, the Todd R Klaenhammer Distinguished Professor at NC State University.Today we are talking to Rodolphe Barrangou. Rodolphe is the Todd R Klaenhammer Distinguished Professor at NC State University. He is a scientist entrepreneur who has co-founded a multitude of biotech companies around CRISPR based approaches including CRISPR Biotechnologies, Ancilia Biosciences, TreeCo and Intellia Therapeutics. He is one of the pioneers in CRISPR-Cas9 dating back to his time as R&D director of genomics at DuPont. In 2007 Rodolphe was the lead author on a Science paper demonstrating proof of the immune function of CRISPR in bacteria.2023-02-031h 00Between the Biotech WavesEpisode 23: A Between the Biotech Waves conversation with Jim Birchenough, Vice Chair of Wells Fargo Biopharmaceutical Inv BankingI am delighted to welcome back Jim Birchenough to Between the Biotech Waves. Jim is Vice Chair Wells Fargo Biopharmaceutical Investment Banking. In 2022 Jim joined the podcast to discuss the market dynamics and learnings from prior market corrections. I am welcoming him back to take stock of where we are, what the bright spots in 2022 were and crystal ball gaze into ’23. What should be watching for as the start of the year unfolds. 2023-01-0856 minBetween the Biotech WavesEpisode 24: A Between the Biotech Waves conversation with John Hoffman, managing director & head of healthcare equity capital markets at Credit SuisseI am delighted to welcome back John Hoffman to Between the Biotech Waves. John is managing director & head of healthcare equity capital markets at Credit Suisse. In mid 2022 John joined the podcast to discuss the market outlook for ’22 and many of his predictions were spot on. It was also one of the most downloaded podcasts of the year. I am welcoming him back to review ’22, lessons learned and crystal ball gaze into ’23. What are we seeing overall in the capital markets, is M&A now on the horizon and what should pre-IPO companies be thinking about. 2023-01-0851 minBetween the Biotech WavesA Between the Biotech Waves Conversation with Jeremy Levin, Chair & CEO of Ovid TherapeuticsToday we are talking to Jeremy Levin. Jeremy is chairman and CEO of Ovid Therapeutics, focused on rare and orphan disease of the CNS. He is the immediate past chair of BIO. Jeremy has a storied career in biotech having served as president and CEO of Teva Pharmaceutica’s, a member of the exec committee of BMS where he had global responsibilities for strategy, alliances and transactions. There he devised the “String of Pearls” BD strategy which led to the acquisition of Medarex and opened the path to the successful development of the first i-onc drugs. Prior to BMS...2023-01-011h 11Between the Biotech WavesEpisode 21 A Between the Biotech Waves conversation with Laksh Aithani Co-founder & CEO of Charm TherapeuticsToday we are talking to Laksh Aithani, Co-founder and CEO of Charm Therapeutics. Laksh is a scientist turned entrepreneur. He received his degree in Natural Sciences from the University of Cambridge. While at University he co-founded Genei, an AI company that automatically summarizes background reading producing blogs, articles and reports (I would note but not podcasts!). He joined Exscientia where he was a core contributor to their AI platform following which he co-founded Charm with David Baker.2022-12-2147 minBetween the Biotech WavesEpisode 20: A Between the Biotech Waves conversation with Tom Barnes, CEO of ORNA TherapeuticsToday we are talking to Tom Barnes. Tom is CEO of Orna Therapeutics, a circular RNA focused biotech developing in situ CAR therapeutics. Orna recently announced a series B with a multi billion $ mega-deal with Merck. Prior to Orna Tom and I worked together at Intellia and also Ascelagen. Tom has also had leading positions at Eleven Bio and Millennium. Tom has deep biological pathway domain expertise and has worked across a broad range of therapeutic modalities, from genome editing, to RNA therapeutics, small molecules and proteins. Tom is a true scientist and drug hunter. 2022-10-2553 minBetween the Biotech WavesEpisode 19: A Between the Biotech Waves Conversation with JeanFrancois Formela, Partner at Atlas Venture & multi-biotech company founderToday we are talking to JeanFrancois Formela. I have known JF for over 2 decades having worked with him at Atlas in building multiple biotech companies. JF is a partner at Atlas Venture which he joined in 1993 to build the US LS presence which has ultimately become the Atlas we all know today. He co-founded, invested in and played pivotal roles in a multitude of companies including Intellia Therapeutics, IFM Therapeutics, Korro Bio, Triplet and others. Other key investments he has made include Exelixis, Adnexus (acqd byBMS), Arteaus (acqd by Eli Lilly), CoStim Pharmaceuticals (acqd byNovartis) and Translate Bio (acqd...2022-10-1550 minBetween the Biotech WavesEpisode 18: A Between the Biotech Waves conversation with Ram Aiyer, CEO of RNA base editing company Korro BioToday we are talking to Ram Aiyer. Ram is CEO of Korro Bio, an RNA base editing company focused on co-opting ADAR, a naturally present editing system in all our cells to base edit A to I (which is translated as a G) in RNA. Prior to Korro, Ram was CBO and CFO of Corvidia, a company he successfully helped build and sell to Novo Nordisk for 2.1Bn$. Prior to Corvidia he was an EIR at BioHealth Innovation. He started his scientific career at Janssen Pharmaceuticals and held leadership roles at FlowMetric, Sofinnova Partners, and JP Morgan Chase.2022-10-111h 07Between the Biotech WavesEpisode 17: A Between the Biotech Waves conversation with Regina Jorgensen, Director of the Maria Mitchell Observatory.In this episode we discuss the formation and evolution of galaxies, our expanding universe, the big bang, the source of fast radio bursts, the James Webb Space Telescope and of course.....Aliens!2022-10-011h 07Between the Biotech WavesEpisode 16: A Between the Biotech Waves conversation with Abraham Heifets CEO of AtomwiseToday we talk to Abe Heifets, CEO of Atomwise, a biotech company focusing on the utilization of AI for drug discovery. Atomwise recently (post this recording) announced a $1.2B discovery deal with Sanofi. We discuss AI, its use in drug discovery and development, recent advances and the potential sentient nature of AI. Enjoy.2022-09-291h 00Between the Biotech WavesEpisode 15: A Between the Biotech Waves Conversation with Rodger Novak and Shaun Foy, co-founders with Emmanuelle Charpentier of CRISPR TherapeuticsDiscussing the formation of CRISPR Tx, the positives, negatives and everything in between. This is the first time all three of us reconnected since our respective departures from our founding roles and features some candid moments from our respective journeys. Enjoy.2022-09-141h 07Between the Biotech WavesEpisode 14: A Between the Biotech Waves Conversation with Paul Matteis, Managing Director of Biotechnology Equity Research at Stifel2022-09-011h 00Between the Biotech WavesEpisode 13: A Between the Biotech Waves Conversation with Vic Myer, President and CSO at Chroma MedicineToday we talk to Vic Myer, xChief Technology Officer at Editas, currently President and CSO at Chroma Medicine. We discuss the state of genome editing and the potential for chromatin modification.2022-08-2552 minBetween the Biotech WavesEpisode 12: A Between the Biotech Waves conversation with Geoff Meacham, Managing Director of Equity Research at Banc of America covering Biotechnology and Major Pharmaceuticals in the US.2022-08-1853 minBetween the Biotech WavesEpisode 11: A Between the Biotech Waves conversation with Prof Robert Langer. In this episode we discuss nanoparticle delivery systems and the evolution of drug discovery.2022-08-1851 minBetween the Biotech WavesEpisode 9: A Between the Biotech Waves Conversation with Yaron Werber, MD of Healthcare Biotechnology at Cowen.Today we are talking to Yaron Werber. Yaron is Managing Director of Healthcare Biotechnology at Cowen, he has over 20 years of experience as a research analyst and was a founding team member, chief business and financial officer of Ovid Therapeutics. Prior to Ovid Yaron was managing director and head of US healthcare and biotech equity research at Citi.Please note - Between vacation, other work commitments and COVID this conversation was recorded over 2 weeks ago. During that time the tea leave reading of the biotech market has marched forward with people highlighting the double bottom and climb...2022-07-2752 minBetween the Biotech WavesEpisode 10: A Between the Biotech Waves Conversation with Eric Topol focusing on COVID & AI in healthcareIn this episode we are talking to Prof Eric Topol. Eric is a cardiologist by training, a basic scientist in the areas of personalized genomic medicine at the interface between genetics and digital health and is the author of the leading textbook in interventional cardiology in addition to authoring books on AI in medicine. He is the founder and director of the Scripps Research Translational Institute, a professor of molecular medicine at the scripps research institute and a snr consultant at the division of cardiovascular diseases at Scripps Clinic in La Jolla CA. Finally, he is editor in chief...2022-07-2749 minBetween the Biotech WavesEpisode 7 A conversation with John Hoffman Managing Director & head of Healthcare ECM at Credit SuisseA Between the Biotech Waves conversation with John Hofffman, managing director & head of healthcare equity capital markets at Credit Suisse. John has nearly two decades of experience in supporting healthcare companies in the public markets. In this episode we discuss the current market dynamics from a equity capital market perspective.2022-06-2251 minBetween the Biotech WavesEpisode 8 John Leonard CEO of Intellia TherapeuticsA Between the Biotech Waves conversation with John Leonard, CEO of Intellia Therapeutics. John has over 30 years of experience in drug research & development. Prior to joining Intellia John was CSO at Abbvie. In this episode we discuss the formation of Intellia, some of the challenges and the recent data announced in ATTR.2022-06-2149 minBetween the Biotech WavesA Between The Biotech Waves Conversation With William Hicks, Co-Chair of Securities & Capital Markets Mintz LevinToday I talk to William Hicks, co-chair of securities and capital markets at Mintz Levin. We discuss the state of the capital markets, financing options for companies and the challenges companies face in this market.2022-06-0953 minBetween the Biotech WavesA Between The Biotech Waves Conversation With Jim Birchenough, Vice Chair Wells Fargo Biopharmaceutical Investment BankingA discussion of the current market volatility and options for public biotech companies with Jim Birchenough Vice Chair Wells Fargo Biopharmaceutical Investment Banking 2022-06-0941 minBetween the Biotech WavesA Between The Biotech Waves Conversation With Sumit Khedekar, Head of Healthcare of the Americas Investment Banking at CitiA discussion of the current market volatility and options for public biotech companies with Sumit Khedekar, Head of Healthcare Investment Banking at Citi 2022-06-0951 minBetween the Biotech WavesA Between The Waves Conversation with Julia Vitarello, the mother of Mila and co-developer of MilasenA conversation with Julia Vitarello, founder of Mila's Miracle Foundation and co-founder of the N=1 Collaborative. Julia, in partnership with Dr Tim Yu, developed the first N of 1 genetic medicine to treat her daughter Mila2022-05-261h 05Between the Biotech WavesA Between The Biotech Waves Conversation with Sek Kathiresan, founder & CEO of Verve TherapeuticsA Conversation With Sek Kathiresan MD, founder and CEO of Verve Therapeutics2022-05-2637 min
Between the Biotech WavesA Between The Waves Conversation With Rich Ross, Technical Analyst at Evercore2022-05-2139 min
Triplet Therapeutics, Part 1Nessan Bermingham is founder and CEO of Triplet Therapeutics, Inc. He is a serial biotech entrepreneur and investor who has founded several companies including Triplet, Korro Bio and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company,” taking the company from concept to IPO and large partnering deals with approximately 200 employees. He has nearly two decades of experience in Life Sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets. As a venture partner at Atlas Venture and managing partner at Omega Funds, he successfully invested in and managed...2020-07-1524 min
Help 4 HD Live!Triplet Therapeutics, Part 1Nessan Bermingham is founder and CEO of Triplet Therapeutics, Inc. He is a serial biotech entrepreneur and investor who has founded several companies including Triplet, Korro Bio and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company,” taking the company from concept to IPO and large partnering deals with approximately 200 employees. He has nearly two decades of experience in Life Sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets. As a venture partner at Atlas Venture and managing partner at Omega Funds, he successfully invested in and managed...2020-07-1523 min
BioBossNessan Bermingham: CEO of Triplet Therapeutics"Be very fair. You don't know it all. And be willing to actually listen to people. And when you're wrong, tell people you're wrong." - Nessan Bermingham: Founder, President and CEO of Triplet Therapeutics2020-01-2651 min